Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist wins FDA nod for antibiotic Zerbaxa

This article was originally published in Scrip

Executive Summary

Before its acquisition of Cubist Pharmaceuticals was barely underway, Merck's 9.5bn bid for the company already has garnered it a nice payoff – the US approval on 19 December of Zerbaxa (ceftolozane/tazobactam), a new combination antibiotic intended to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

You may also be interested in...



Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.

Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move

Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.

Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors

The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.

Topics

Related Companies

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel